26 September 2014

Share Purchase Plan – Underwritten

Antisense Therapeutics Limited ("ANP" or the "Company") is pleased to announce that as foreshadowed in the 25 September 2014 announcement regarding a planned $2.5 million capital raising, it has today executed an underwriting agreement with Patersons Securities Limited pursuant to the offer of a Share Purchase Plan ("SPP") to all eligible shareholders in Australia and New Zealand.

Under the SPP, eligible shareholders will be able to subscribe for up to $15,000 of new shares per shareholder, at 11.5c per share. The SPP is targeting a capital raising of $1.5 million and is underwritten by Patersons Securities to $1 million (utilising available placement capacity).

The SPP permits the Company's approximately 3,000 eligible shareholders to participate in the capital raising on the same basis as the recent placement by the Company.

Further details of the underwriting arrangements, and the terms and conditions of the SPP, will be set out in an offer letter that will be sent to shareholders on Tuesday 7 October 2014.

SPP Timetable

The proposed timetable for the SPP is detailed below. The Directors reserve the right to vary the dates and times without notice.

Event	Date
Record Date to determine eligibility to participate in the SPP.	7.00 PM AEST on Wednesday, 24 September
Announcement of SPP to ASX.	Thursday, 25 September 2014
Lodgement of SPP Offer Document with ASX.	Thursday, 2 October 2014
Dispatch of SPP documentation to Eligible Shareholders.	Tuesday, 7 October 2014
Opening of the SPP.	Tuesday, 7 October 2014
Closing Date of the SPP.	5:00 PM AEDT on Friday, 31 October 2014
Shortfall Notification to Underwriter.	Wednesday, 5 November 2014
Allotment and Issue of Shares under the SPP and lodgement of Appendix 3B with ASX.	Wednesday, 12 November 2014
Dispatch Date.	By Friday, 14 November 2014

Contact Information:
Website: www.antisense.com.au
Company Secretary: Phillip Hains +61 (0)3 9824 5254

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS) , ATL1103 a second-generation antisense drug designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-I levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.